Company profile
PaxMedica, Inc. Common Stock
OTC: PXMD · Healthcare · Biotechnology
#1163 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ 7GM —SS 17
v0.1 · 25/100 weight · pillars only
↑ balance-sheet leverage, Piotroski F · ↓ disclosure history, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$18.3M
Employees
6
as of 2026-10-15
Market cap
$63.1k
as of 2026-10-15
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$18.3M-$18.3M2023
Operating income-$16.1M-$16.1M2023
Total assets$5.7M$5.7M2023
Liabilities$2.3M$2.3M2023
Equity$3.4M$3.4M2023
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is PaxMedica, Inc. Common Stock’s revenue?
PaxMedica, Inc. Common Stock booked $0 in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
NanoSphere Health Sciences Inc.——Many Bright Ideas Technologies Inc.——Priority Aviation, Inc.——Digicann Ventures Inc.16DAlternative Energy Partners, Inc.——ProtoKinetix, Incorporated——Neighbors
Westchester →Key facts
CEOHoward J. Weisman
SectorHealthcare
IndustryBiotechnology
HeadquartersTarrytown, NY
ExchangeOTC: PXMD
Employees6
IPO date2022-08-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.